This company has shut down. Imara is no longer operating — its last tracked round was a Post-IPO Equity in 2021.
Explore the Startup GraveyardImara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Imara has raised $50.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in July 2021.
Imara's investors include RA Capital Management, New Enterprise Associates, Pfizer, OrbiMed, Rock Springs Capital.
Imara is headquartered in Cambridge, United States.
Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.
Imara is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Imara — Funding & Investors." VCBacked, July 14, 2021, https://www.vcbacked.co/company/imara. Accessed August 12, 2026.
VCBacked. (2021). Imara — Funding & Investors. Retrieved August 12, 2026, from https://www.vcbacked.co/company/imara
{{cite web |title=Imara — Funding & Investors |url=https://www.vcbacked.co/company/imara |website=VCBacked |access-date=August 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated